LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
LENZ Therapeutics (NASDAQ:LENZ) has announced the commercial availability of VIZZ™, their FDA-approved aceclidine-based eye drop treatment for presbyopia in adults. The product is being distributed as samples to eye care professionals nationwide, with commercial shipments starting in October through their ePharmacy partner.
VIZZ is notable as the first and only aceclidine-based eye drop approved for presbyopia, targeting a market of approximately 128 million adults in the United States. The treatment works through a pupil-selective miotic mechanism, achieving sub-2mm pupil size to improve near vision for up to 10 hours. Clinical trials showed 93% of participants achieved 20/40 or better near vision within 30 minutes.
LENZ Therapeutics (NASDAQ:LENZ) ha annunciato la disponibilità commerciale di VIZZ™, il loro collirio a base di aceclidina approvato dalla FDA per la presbiopia negli adulti. Il prodotto viene distribuito come campioni agli specialisti della cura oculare in tutto il paese, con spedizioni commerciali previste a partire da ottobre tramite il partner ePharmacy.
VIZZ è noto per essere il primo e unico collirio a base di aceclidina approvato per la presbiopia, rivolgendosi a un mercato di circa 128 milioni di adulti negli Stati Uniti. Il trattamento agisce tramite un meccanismo miótico selettivo della pupilla, riducendo la dimensione della pupilla a meno di 2 mm per migliorare la visione da vicino per fino a 10 ore. negli studi clinici, il 93% dei partecipanti ha raggiunto una visione da vicino 20/40 o migliore entro 30 minuti.
LENZ Therapeutics (NASDAQ:LENZ) ha anunciado la disponibilidad comercial de VIZZ™, su tratamiento para la presbicia en adultos basado en aceclidina, aprobado por la FDA. El producto se está distribuyendo como muestras a profesionales de la salud ocular en todo el país, con envíos comerciales a partir de octubre a través de su socio ePharmacy.
VIZZ es notable como el primer y único colirio basado en aceclidina aprobado para la presbicia, dirigido a un mercado de aproximadamente 128 millones de adultos en Estados Unidos. El tratamiento actúa mediante un mecanismo miótico selectivo de la pupila, logrando un tamaño pupilar de menos de 2 mm para mejorar la visión de cerca durante hasta 10 horas. En los ensayos clínicos, el 93% de los participantes alcanzó 20/40 o mejor de visión cercana en 30 minutos.
LENZ Therapeutics (NASDAQ:LENZ)가 FDA 승인을 받은 VIZZ™를 성인 노안 치료제로 상용 가능하게 발표했습니다. 이 제품은 전국의 안과 전문의에게 샘플로 배포되며, 10월부터 ePharmacy 파트너를 통해 상용 선적이 시작됩니다.
VIZZ는 노안용으로 승인된 최초이자 유일한 aceclidine 기반 점안제로, 미국 내 약 1.28억 명의 성인 시장을 겨냥합니다. 이 치료제는 동공 선택적 축삭수축 메커니즘을 통해 동공 크기를 2mm 미만으로 만들어 근거리 시력을 최대 10시간까지 개선합니다. 임상 시험에서 참가자 중 93%가 30분 이내에 근거리 시력 20/40 이상을 달성했습니다.
LENZ Therapeutics (NASDAQ:LENZ) a annoncé la disponibilité commerciale de VIZZ™, leur collyre à base d’acéclidine approuvé par la FDA pour la presbytie chez les adultes. Le produit est distribué sous forme d’échantillons aux professionnels de la vue à l’échelle nationale, les expéditions commerciales devant débuter en octobre via leur partenaire ePharmacy.
VIZZ se distingue comme le premier et unique collyre à base d’acéclidine approuvé pour la presbytie, ciblant un marché d’environ 128 millions d’adultes aux États‑Unis. Le traitement agit par un mécanisme myotique sélectif de la pupille, réduisant la taille de la pupille à < 2 mm pour améliorer la vision de près pendant jusqu’à 10 heures. Dans les essais cliniques, 94% des participants ont obtenu une vision de près de 20/40 ou mieux en 30 minutes.
LENZ Therapeutics (NASDAQ:LENZ) hat die kommerzielle Verfügbarkeit von VIZZ™ angekündigt, ihrer von der FDA zugelassenen aceclidin-basierten Augentropfenbehandlung für Presbyopie bei Erwachsenen. Das Produkt wird landesweit als Muster an Augenärzte verteilt, mit kommerziellen Lieferungen ab Oktober über ihren ePharmacy-Partner.
VIZZ ist bemerkenswert als erstes und einziges aceclidin-basiertes Augentropfenmittel, das für Presbyopie zugelassen ist, und richtet sich an einen Markt von ca. 128 Millionen Erwachsenen in den USA. Die Behandlung wirkt durch einen Pupillen-spezifischen miotischen Mechanismus und erreicht eine Pupillengröße von unter < 2 mm, um die Nahsicht bis zu 10 Stunden zu verbessern. In klinischen Studien erreichten 93% der Teilnehmer innerhalb von 30 Minuten 20/40 oder besser nahes Sehen.
LENZ Therapeutics (بورصة ناسداك: LENZ) أعلنت عن التوفر التجاري لـ VIZZ™، وهو قطرات عين баз aceclidine المعتمدة من FDA لعلاج الشيخوخة القزحية لدى البالغين. يتم توزيع المنتج كعينات على أطباء العيون في جميع أنحاء البلاد، على أن تبدأ الشحنات التجارية في أكتوبر من خلال شريكهم ePharmacy.
VIZZ جدير بأن يكون أول وأوحد قطرة عين قائمة على aceclidine معتمدة لعلاج قصر البصر الشيخوخي، مستهدفًا سوقًا ي قدر بـ 128 مليون بالغ في الولايات المتحدة. يعمل العلاج عبر آلية ميُّوكية انتقائية للبؤبؤ، محققًا تقليصًا لبؤبؤ العين إلى ما دون < 2 مم لتحسين الرؤية القريبة حتى 10 ساعات. أظهرت التجارب السريرية أن 93% من المشاركين حققوا رؤية قريبة بمقدار 20/40 أو أفضل خلال 30 دقيقة.
LENZ Therapeutics (纳斯达克证券交易所: LENZ) 宣布其经过美国食品药品监督管理局（FDA）批准的以aceclidine为基础的眼药水治疗近视老花（成人）VIZZ™的商业化可用性。该产品以样品形式分发给全国的眼科专业人员，商业发货预计将于十月通过其ePharmacy合作伙伴开始。
VIZZ 的突出之处在于 第一款也是唯一一款以aceclidine为基础的眼药水，获批用于治疗近视老花，面向美国约 1.28亿成人的市场。治疗通过对瞳孔的选择性缩小机制，使瞳孔小于2毫米，从而在最多 10 小时内改善近距离视力。在临床试验中，93% 的参与者在 30 分钟内达到了近处视力 20/40 或更好。
- First-to-market position as the only FDA-approved aceclidine-based eye drop for presbyopia
- Large target market of 128 million adults in the United States
- Strong clinical efficacy with 93% of participants achieving 20/40 or better near vision
- Long duration of effect lasting up to 10 hours
- Multiple distribution channels including ePharmacy and retail pharmacies
- Gradual rollout may limit initial market penetration
- Product availability not fully nationwide until mid-Q4 2025
Insights
LENZ's VIZZ launch targets massive presbyopia market with unique mechanism, initiating nationwide distribution with commercial shipments starting October.
LENZ Therapeutics has hit a critical commercialization milestone with the launch of VIZZ, marking the company's transition from development to revenue generation. This first-in-class aceclidine-based eye drop for presbyopia enters a substantially untapped market of approximately 128 million adults in the United States suffering from age-related near vision difficulties.
What makes VIZZ particularly compelling is its novel mechanism of action as a predominantly pupil-selective miotic with minimal ciliary muscle stimulation. By contracting the iris sphincter muscle to create a sub-2mm pupil, VIZZ extends depth of focus without causing myopic shift – a significant differentiation from competitive approaches. The product demonstrated impressive efficacy in Phase 3 trials with 93% of participants achieving functional near vision (20/40 or better) within 30 minutes, lasting up to 10 hours.
The company's phased commercial rollout strategy is executing on schedule, with sales representatives already distributing professional samples nationwide to eye care professionals. Full commercial availability will follow in October through their ePharmacy partner, expanding to retail pharmacies by mid-Q4 2025. This sequential approach allows LENZ to build prescriber awareness and comfort with the product before broad consumer access.
LENZ positions VIZZ as a "Category of One" treatment, emphasizing its uniqueness in the presbyopia market. The company appears well-prepared for commercial execution, with management noting "extremely positive" initial feedback and early brand awareness among eye care professionals – critical gatekeepers for prescription products. The sizable addressable market and VIZZ's differentiated profile could represent substantial revenue potential if the company executes effectively on this launch.
VIZZ sample distribution initiated nationwide to Eye Care Professionals
Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025
VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia for up to 10 hours, a condition impacting approximately 128 million adults in the United States
SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), today announced VIZZ (aceclidine ophthalmic solution)
“We are thrilled to introduce VIZZ to the 128 million adults living with blurry near vision in the United States,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “The team has been preparing for this moment for months and worked tirelessly to enable the availability of product samples and commercial product following our FDA approval. Initial feedback and early brand awareness from the ECP community is extremely positive, and we feel well-positioned for a successful product launch, firmly establishing VIZZ as a Category of One for the treatment of presbyopia.”
VIZZ is powered by aceclidine, differentiated by its mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation. VIZZ contracts the iris sphincter muscle, resulting in a pinhole effect and uniquely achieves a sub-2mm pupil that extends depth of focus to significantly improve near vision without causing a myopic shift. In the CLARITY Phase 3 clinical trial,
“With VIZZ now available, we’re giving people living with presbyopia a simple, fast-acting way to see up close again,” said Shawn Olsson, Chief Commercial Officer of LENZ Therapeutics. “It’s about restoring everyday confidence, including reading a phone, checking a price tag, or enjoying your active lifestyle glasses-free. We’re excited to bring this new option to millions who want more freedom in their near vision.”
For more information about VIZZ and full prescribing information, please visit www.VIZZ.com.
About Presbyopia
Presbyopia is the inevitable loss of near vision associated with aging. It impacts the daily lives of nearly all people over the age of 45. As people age, the crystalline lens in their eyes gradually hardens and becomes less able to change shape. This loss of elasticity of the lens reduces the ability of the lens to focus incoming light from near objects onto the retina. Adults over age 50 lose, on average, 1.5 lines of near vision every six years. Although the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced starting in their mid-40s, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work. Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed, after evaluation by an ECP, with prescription reading or bifocal glasses or multifocal contact lenses.
About VIZZ (aceclidine ophthalmic solution)
VIZZ (aceclidine ophthalmic solution)
VIZZ Indication and Important Safety Information
INDICATION
VIZZ (aceclidine ophthalmic solution)
IMPORTANT SAFETY INFORMATION
- Do not use VIZZ if allergic to any of the ingredients.
- To help avoid potential eye injury or contamination of the product, do not allow the vial tip to touch the eye or any surfaces. Discard the opened vial immediately after use.
- Contact lenses should be removed before using VIZZ. After dosing, contact lenses can be reinserted after 10 minutes.
- If using more than one topical eye medication, the medicines should be administered at least 5 minutes apart.
- Temporary dim or dark vision may be experienced after using VIZZ. Do not drive or operate machinery if vision is not clear.
- Seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced.
ADVERSE REACTIONS
The most common reported adverse reactions of participants were instillation site irritation (
For additional information, please see the full Prescribing Information available at www.VIZZ.com.
About LENZ Therapeutics
LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmic solution)
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. You can identify forward-looking statements by words such as “may,” “will,” “could,” “can,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “poised,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, but not all forward-looking statements will contain these words. ” Forward-looking statements in this press release include statements regarding the timing and availability of VIZZ; potential market size for VIZZ; its ability to meet patient needs and become standard of care; LENZ commercialization plans, including international partnering plans, and the quotations of LENZ management. These statements are based on numerous assumptions concerning VIZZ, target markets and involve substantial risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievement to be materially different from the information expressed or implied by these forward-looking statements, including those risk factors described in the section titled “Risk Factors” in our Quarterly Report on Form 10-Q filed for the quarter ended June 30, 2025 and our subsequent filings with the SEC. We cannot assure you that the forward-looking statements in this press release or the assumptions upon which they are based will prove to be accurate. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, LENZ disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Contact:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
FAQ
When will VIZZ eye drops be available to consumers?
How effective is VIZZ for treating presbyopia?
What makes VIZZ different from other presbyopia treatments?
How many people could potentially benefit from LENZ Therapeutics' VIZZ?
How long do the effects of VIZZ eye drops last?
